Loading stock data…
LEU
$213.22+5.89 (+2.84%)
Pre-Market$210.14-3.08 (-1.44%)· Last close May 11
Centrus Energy Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Centrus Energy Corp. in the Energy sector is trading at $213.22. The stock is currently 54% below its 52-week high of $464.25, remaining 15.2% below its 200-day moving average. Technical signals show neutral RSI of 56 and bullish MACD crossover, explaining why LEU maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
XOMCVXCOP
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$213.22
Potential Downside
62.6%
Whystock Fair Value$79.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$278.64+30.7%
Range$195.00 – $390.00
Fundamentals
Centrus Energy Corp. supplies nuclear fuel components for the nuclear power industry in the United States, Belgium, Japan, the Netherlands, and internationally. The company operates in two segments, Low-Enriched Uranium (LEU) and Technical Solutions....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.27B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
55.52
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.70%
Volume
Today's trading volume
1.08M
Recent News
Centrus Energy Q1 Earnings Call Highlights
Centrus Energy (NYSE:LEU) reported higher first-quarter revenue and raised its full-year revenue outlook, citing commercial progress, improving offtake discussions and continued work on its uranium enrichment expansion program. On the company’s Q1 2026 earnings call, President and Chief Executive O
A Look At Centrus Energy (LEU) Valuation As Mixed Share Performance Meets Contrasting Analyst Targets
Why Centrus Energy is on investors’ radar today Centrus Energy (LEU) has drawn fresh attention after a period of mixed share performance, with a strong 1 year total return alongside weaker recent moves. This has prompted investors to reassess what is driving the stock. See our latest analysis for Centrus Energy. The recent 11% one day share price decline, alongside a 22% 90 day share price fall, contrasts sharply with an 18.9% 30 day share price gain and a very large 5 year total shareholder...
Why Wall Street Remains Bullish On Centrus Energy (LEU) Despite Near-Term Pressure
With an upside potential of 23.29%, Centrus Energy Corp. (NYSE:LEU) is among the 8 Best Energy Infrastructure Stocks That Will Skyrocket. On April 24, B. Riley lowered its price target on Centrus Energy Corp. (NYSE:LEU) to $295 from $315 while maintaining a Buy rating on the shares. The adjustment reflects anticipated near-term cost pressures associated with the […]
Should You Buy, Hold or Sell UUUU Stock Post Q1 Earnings?
Energy Fuels jumps after Q1 revenues more than doubled on uranium sales, even as the company posted a slightly wider-than-expected loss.
Palantir Stock Is a Defining AI Investment. Now Its Executives Want to Make Sure You Know It’s Not ‘AI Slop.’
Despite a year-to-date decline, Palantir continues to deliver accelerating U.S. commercial growth, strong cash flow, and high-profile partnerships, prompting analysts and investors to debate whether PLTR stock deserves its premium valuation.